Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypogonadism | 2 | 2020 | 284 | 0.640 |
Why?
|
| Testosterone | 2 | 2020 | 533 | 0.490 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 414 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1267 | 0.410 |
Why?
|
| Weight Loss | 3 | 2022 | 481 | 0.390 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 259 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 335 | 0.340 |
Why?
|
| Bone Density | 2 | 2024 | 319 | 0.340 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 355 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 488 | 0.330 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 21 | 0.230 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1547 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 1270 | 0.200 |
Why?
|
| Body Composition | 2 | 2024 | 521 | 0.190 |
Why?
|
| Obesity | 2 | 2024 | 2247 | 0.180 |
Why?
|
| Signal Transduction | 2 | 2016 | 4531 | 0.180 |
Why?
|
| Androgen-Insensitivity Syndrome | 2 | 2011 | 25 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 64 | 0.160 |
Why?
|
| Remote Consultation | 1 | 2018 | 24 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2020 | 266 | 0.150 |
Why?
|
| Reproduction | 1 | 2020 | 236 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2016 | 1501 | 0.140 |
Why?
|
| Habenula | 1 | 2018 | 41 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 504 | 0.140 |
Why?
|
| Precision Medicine | 2 | 2011 | 319 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 266 | 0.130 |
Why?
|
| Endocrinology | 1 | 2018 | 134 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 56 | 0.130 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2016 | 35 | 0.130 |
Why?
|
| Brain Mapping | 1 | 2018 | 398 | 0.120 |
Why?
|
| Biomarkers | 2 | 2024 | 3081 | 0.120 |
Why?
|
| Quinazolines | 1 | 2016 | 174 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2016 | 1701 | 0.100 |
Why?
|
| Castration | 1 | 2012 | 33 | 0.100 |
Why?
|
| Chromones | 1 | 2012 | 22 | 0.100 |
Why?
|
| Androstadienes | 1 | 2012 | 49 | 0.100 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 90 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 57 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2012 | 404 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3349 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2009 | 97 | 0.080 |
Why?
|
| Male | 7 | 2024 | 61463 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1695 | 0.070 |
Why?
|
| Mutation | 2 | 2011 | 5848 | 0.070 |
Why?
|
| Disease Progression | 1 | 2012 | 2062 | 0.060 |
Why?
|
| Humans | 10 | 2024 | 125086 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1398 | 0.060 |
Why?
|
| Androgens | 2 | 2020 | 274 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 2792 | 0.050 |
Why?
|
| Phenotype | 1 | 2012 | 4260 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 1939 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 76 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2020 | 75 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 415 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1698 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2011 | 806 | 0.040 |
Why?
|
| Aged | 3 | 2022 | 19861 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 197 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 196 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 293 | 0.040 |
Why?
|
| Estradiol | 1 | 2020 | 532 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 26926 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 306 | 0.030 |
Why?
|
| Taxoids | 1 | 1996 | 67 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2018 | 359 | 0.030 |
Why?
|
| Connectome | 1 | 2018 | 99 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1996 | 130 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 101 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 74 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2016 | 109 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 235 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 463 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 672 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 702 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 813 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1533 | 0.030 |
Why?
|
| Insulin | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 888 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 29632 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2890 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3299 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5175 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 4638 | 0.020 |
Why?
|
| Algorithms | 1 | 1996 | 1629 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 114 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2312 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 368 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1893 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 399 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 767 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 680 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3570 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4390 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 875 | 0.020 |
Why?
|
| United States | 1 | 2018 | 10912 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 16326 | 0.010 |
Why?
|
| Solutions | 1 | 1996 | 65 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 1996 | 105 | 0.010 |
Why?
|
| Solvents | 1 | 1996 | 45 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1996 | 295 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 292 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34218 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1996 | 1080 | 0.010 |
Why?
|
| Female | 1 | 2018 | 66747 | 0.010 |
Why?
|